董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Terry Allison Rappuhn | 女 | Director | 60 | 39.50万美元 | 未持股 | 2017-03-20 |
| John N. Kapoor | 男 | Chairman of the Board | 73 | 40.00万美元 | 未持股 | 2017-03-20 |
| Ronald M. Johnson | 男 | Director | 71 | 38.88万美元 | 未持股 | 2017-03-20 |
| Steven J. Meyer | 男 | Director | 60 | 38.25万美元 | 未持股 | 2017-03-20 |
| Alan Weinstein | 男 | Director | 74 | 39.50万美元 | 未持股 | 2017-03-20 |
| Kenneth S. Abramowitz | 男 | Director | 66 | 36.38万美元 | 未持股 | 2017-03-20 |
| Adrienne L. Graves | 女 | Director | 63 | 39.00万美元 | 未持股 | 2017-03-20 |
| Brian Tambi | 男 | Director | 71 | 35.38万美元 | 未持股 | 2017-03-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Duane A. Portwood | 男 | Chief Financial Officer | 59 | 197.21万美元 | 未持股 | 2017-03-20 |
| Steven Lichter | 男 | Executive Vice President, Pharmaceutical Operations | 66 | 163.78万美元 | 未持股 | 2017-03-20 |
| Randall Pollard | 男 | Senior Vice President, Corporate Controller and Chief Accounting Officer | 53 | 140.94万美元 | 未持股 | 2017-03-20 |
| Jonathon Kafer | 男 | Executive Vice President, Sales and Marketing | 62 | 120.88万美元 | 未持股 | 2017-03-20 |
| Raj Rai | 男 | Chief Executive Officer | 58 | 715.48万美元 | 未持股 | 2017-03-20 |
| Joseph Bonaccorsi | 男 | Executive Vice President, General Counsel, and Secretary | 60 | 248.68万美元 | 未持股 | 2017-03-20 |
| Bruce Kutinsky | -- | Chief Operating Officer | 59 | 250.87万美元 | 未持股 | 2017-03-20 |
董事简历
中英对照 | 中文 | 英文- Terry Allison Rappuhn
-
Terry Allison Rappuhn 她于2015年4月被任命为董事会董事。她曾任职于AGA Medical Holdings公司的董事会，在那里她曾担任董事会审计委员会主席，也曾任职Genesis HealthCare Corporation，在那里她曾担任董事会审计委员会主席，以及合规和薪酬委员会的成员。从1999年到2001年4月，她曾担任Quorum Health Group公司（急症护理医院的所有者和经营者）的高级副总裁兼首席财务官。她曾担任Quorum公司的副总裁、总会计师兼助理财务主管（从1996年到1999年），以及副总裁、内部审计（从1993年到1996年）。她持有Middle Tennessee State University的工商管理学士学位，也是一个注册会计师。
Terry Allison Rappuhn,Ms. Rappuhn has served on the board of directors and as the chair of the audit committee of Quorum Health Corporation, a publicly-held operator of general acute care hospitals and outpatient services, since 2017 and as the Chair of the board of directors of Quorum since March 2018. She has served Akorn, Inc., a publicly-held specialty pharmaceutical company, as a director and member of the audit committee of since 2015 as a member of the nominating and governance committee since 2016 and as the chairperson of the audit committee since 2017. From 2016 to 2017 Ms. Rappuhn served on the board of directors and audit committee of Span-America Medical Systems, Inc. previously a publicly held company that was acquired by Savaria Corporation, a manufacturer of beds and pressure management products for the medical market. From 2006 to 2010 she served as a director and chaired the audit committee of AGA Medical Holdings, Inc. (previously a publicly-held company that was acquired by St. Jude Medical), a medical device company. From 2003 to 2007 she served as a director of Genesis HealthCare Corporation, where she chaired the audit committee. From 1999 to April 2001 Ms. Rappuhn served as Senior Vice President and Chief Financial Officer of Quorum Health Group, Inc., an owner and operator of acute care hospitals. From 1996 to 1999 and from 1993 to 1996 Ms. Rappuhn served as Quorum’s Vice President, Controller and Assistant Treasurer and as Vice President, Internal Audit, respectively. - Terry Allison Rappuhn 她于2015年4月被任命为董事会董事。她曾任职于AGA Medical Holdings公司的董事会，在那里她曾担任董事会审计委员会主席，也曾任职Genesis HealthCare Corporation，在那里她曾担任董事会审计委员会主席，以及合规和薪酬委员会的成员。从1999年到2001年4月，她曾担任Quorum Health Group公司（急症护理医院的所有者和经营者）的高级副总裁兼首席财务官。她曾担任Quorum公司的副总裁、总会计师兼助理财务主管（从1996年到1999年），以及副总裁、内部审计（从1993年到1996年）。她持有Middle Tennessee State University的工商管理学士学位，也是一个注册会计师。
- Terry Allison Rappuhn,Ms. Rappuhn has served on the board of directors and as the chair of the audit committee of Quorum Health Corporation, a publicly-held operator of general acute care hospitals and outpatient services, since 2017 and as the Chair of the board of directors of Quorum since March 2018. She has served Akorn, Inc., a publicly-held specialty pharmaceutical company, as a director and member of the audit committee of since 2015 as a member of the nominating and governance committee since 2016 and as the chairperson of the audit committee since 2017. From 2016 to 2017 Ms. Rappuhn served on the board of directors and audit committee of Span-America Medical Systems, Inc. previously a publicly held company that was acquired by Savaria Corporation, a manufacturer of beds and pressure management products for the medical market. From 2006 to 2010 she served as a director and chaired the audit committee of AGA Medical Holdings, Inc. (previously a publicly-held company that was acquired by St. Jude Medical), a medical device company. From 2003 to 2007 she served as a director of Genesis HealthCare Corporation, where she chaired the audit committee. From 1999 to April 2001 Ms. Rappuhn served as Senior Vice President and Chief Financial Officer of Quorum Health Group, Inc., an owner and operator of acute care hospitals. From 1996 to 1999 and from 1993 to 1996 Ms. Rappuhn served as Quorum’s Vice President, Controller and Assistant Treasurer and as Vice President, Internal Audit, respectively.
- John N. Kapoor
-
John N. Kapoor博士自1990年10月担任董事会主席。Kapoor博士从2001年3月到2002年5月担任临时首席执行官，并从2002年5月到2002年12月担任首席执行官。Kapoor博士是EJ金融股份有限公司总裁，该公司是一家健康护理咨询公司和投资公司。Kapoor博士还是Insys疗法公司（纳斯达克交易代码：INSY）董事会主席，该公司是一家上市的关注于疼痛治疗与肿瘤的药物发展公司，该公司在2010年10月被NeoPharm股份有限公司（此前是一家上市的生物化学制药公司）收购。在被NeoPharm公司收购前，Kapoor博士是该公司董事会主席。按照我们1989年9月20日与John N. Kapoor 信托公司签订的协议，John N. Kapoor博士是受益人以及单一受托人，同时还是董事会主席。Kapoor信托有权指定一人被提名并被董事会推荐参加董事选举。Kapoor博士正是因为此被Kapoor信托公司指定的。
John N. Kapoor has served as the Chairman of our Board since October 1990. Dr. Kapoor served as our interim Chief Executive Officer from March 2001 to May 2002 and as our Chief Executive Officer from May 2002 to December 2002. Dr. Kapoor is the President of EJ Financial Enterprises, Inc., a healthcare consulting and investment company. Dr. Kapoor is a director and former chairman, President and Chief Executive Officer of Insys Therapeutics, Inc. (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology, into which NeoPharm, Inc. (previously a publicly held biopharmaceutical company) merged in October 2010. Prior to NeoPharm's merger, Dr. Kapoor was the chairman of its board of directors. Previously, Dr. Kapoor was the chairman of the board of directors of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. in August 2007. Dr. Kapoor received his Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and a B.S. in Pharmacy from Bombay University in India. Under agreements between Akorn and the John N. Kapoor Trust dated 9/20/89 (the "Kapoor Trust"), the beneficiary and sole trustee of which is Dr. John N. Kapoor, the Kapoor Trust is entitled to designate one individual to be nominated and recommended by our Board for election as a director. Dr. Kapoor was designated by the Kapoor Trust for this purpose. - John N. Kapoor博士自1990年10月担任董事会主席。Kapoor博士从2001年3月到2002年5月担任临时首席执行官，并从2002年5月到2002年12月担任首席执行官。Kapoor博士是EJ金融股份有限公司总裁，该公司是一家健康护理咨询公司和投资公司。Kapoor博士还是Insys疗法公司（纳斯达克交易代码：INSY）董事会主席，该公司是一家上市的关注于疼痛治疗与肿瘤的药物发展公司，该公司在2010年10月被NeoPharm股份有限公司（此前是一家上市的生物化学制药公司）收购。在被NeoPharm公司收购前，Kapoor博士是该公司董事会主席。按照我们1989年9月20日与John N. Kapoor 信托公司签订的协议，John N. Kapoor博士是受益人以及单一受托人，同时还是董事会主席。Kapoor信托有权指定一人被提名并被董事会推荐参加董事选举。Kapoor博士正是因为此被Kapoor信托公司指定的。
- John N. Kapoor has served as the Chairman of our Board since October 1990. Dr. Kapoor served as our interim Chief Executive Officer from March 2001 to May 2002 and as our Chief Executive Officer from May 2002 to December 2002. Dr. Kapoor is the President of EJ Financial Enterprises, Inc., a healthcare consulting and investment company. Dr. Kapoor is a director and former chairman, President and Chief Executive Officer of Insys Therapeutics, Inc. (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology, into which NeoPharm, Inc. (previously a publicly held biopharmaceutical company) merged in October 2010. Prior to NeoPharm's merger, Dr. Kapoor was the chairman of its board of directors. Previously, Dr. Kapoor was the chairman of the board of directors of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. in August 2007. Dr. Kapoor received his Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and a B.S. in Pharmacy from Bombay University in India. Under agreements between Akorn and the John N. Kapoor Trust dated 9/20/89 (the "Kapoor Trust"), the beneficiary and sole trustee of which is Dr. John N. Kapoor, the Kapoor Trust is entitled to designate one individual to be nominated and recommended by our Board for election as a director. Dr. Kapoor was designated by the Kapoor Trust for this purpose.
- Ronald M. Johnson
-
Ronald M. Johnson先生在2003年5月被任命为董事。Johnson先生在Becker合伙人咨询公司担任总裁，该公司是一家在美国食品药品监督管理局监管要求下，向制药、生物和医疗设备领域提供咨询的企业，他一直在改公司任职直到2013年4月从该公司退休。Johnson先生目前担任独立咨询师。在此之前，Johnson先生是Lewin集团的执行副总裁，该公司是Quintiles跨国股份有限公司的子公司，该跨国公司向国家、联邦政府、医疗保健保险人以及医疗保健机构提供各类医疗保健咨询服务。在加入Lewin公司前，从1997年到2006年，Johnson先生担任Quintiles咨询公司执行副总裁，该公司是Quintiles跨国股份有限公司业务部门的一部分。Quintiles咨询公司向制药、医疗设备、生物和生物科技领域提供咨询服务，并满足美国食品药品监督管理局的要求。Johnson先生还在美国食品药品监督管理局任职30年，并在合规和执行领域担任各类高级职务。
Ronald M. Johnson was appointed a director by the Board in May 2003. Mr. Johnson served as President of Becker & Associates Consulting, a firm which provides consulting services to the pharmaceutical, biologics and medical device industries on FDA regulatory requirements, from 2011 until retiring from that firm in 2013 and currently continues to serve as an independent consultant. Previously, Mr. Johnson served as Executive Vice President of The Lewin Group, a subsidiary of Quintiles Transnational, Inc., which provides various healthcare consulting services to state and federal governments, healthcare insurers and healthcare institutions. Prior to joining The Lewin Group, Mr. Johnson served as Executive Vice President of Quintiles Consulting, a business unit of Quintiles Transnational, Inc. Quintiles Consulting provides consulting services to the pharmaceutical, medical device, biologic and biotechnology industries in their efforts to meet FDA regulatory requirements. Mr. Johnson also spent 30 years with the FDA, holding various senior level positions primarily in the compliance and enforcement areas. - Ronald M. Johnson先生在2003年5月被任命为董事。Johnson先生在Becker合伙人咨询公司担任总裁，该公司是一家在美国食品药品监督管理局监管要求下，向制药、生物和医疗设备领域提供咨询的企业，他一直在改公司任职直到2013年4月从该公司退休。Johnson先生目前担任独立咨询师。在此之前，Johnson先生是Lewin集团的执行副总裁，该公司是Quintiles跨国股份有限公司的子公司，该跨国公司向国家、联邦政府、医疗保健保险人以及医疗保健机构提供各类医疗保健咨询服务。在加入Lewin公司前，从1997年到2006年，Johnson先生担任Quintiles咨询公司执行副总裁，该公司是Quintiles跨国股份有限公司业务部门的一部分。Quintiles咨询公司向制药、医疗设备、生物和生物科技领域提供咨询服务，并满足美国食品药品监督管理局的要求。Johnson先生还在美国食品药品监督管理局任职30年，并在合规和执行领域担任各类高级职务。
- Ronald M. Johnson was appointed a director by the Board in May 2003. Mr. Johnson served as President of Becker & Associates Consulting, a firm which provides consulting services to the pharmaceutical, biologics and medical device industries on FDA regulatory requirements, from 2011 until retiring from that firm in 2013 and currently continues to serve as an independent consultant. Previously, Mr. Johnson served as Executive Vice President of The Lewin Group, a subsidiary of Quintiles Transnational, Inc., which provides various healthcare consulting services to state and federal governments, healthcare insurers and healthcare institutions. Prior to joining The Lewin Group, Mr. Johnson served as Executive Vice President of Quintiles Consulting, a business unit of Quintiles Transnational, Inc. Quintiles Consulting provides consulting services to the pharmaceutical, medical device, biologic and biotechnology industries in their efforts to meet FDA regulatory requirements. Mr. Johnson also spent 30 years with the FDA, holding various senior level positions primarily in the compliance and enforcement areas.
- Steven J. Meyer
-
Steven J. Meyer先生在2009年6月被任命为董事。自2005年Meyer先生担任JVM房地产股份有限公司首席财务官，该公司是以及私人企业，并主要关注于并购、再定位以及为有资质的投资者进行多房产管理。Meyer先生现任职于INSYS疗法公司董事会。INSYS先生任职于Baxter国际股份有限公司的23个年头中，还担任过财务主管、国际业务会计账以及负责全球运营的副总裁。
Steven J. Meyer was appointed a director by the Board in June 2009. Since 2005 Mr. Meyer has served as the Chief Financial Officer of JVM Realty, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company that provides renal and hospital products. Mr. Meyer served as the Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at Baxter International, Inc. Mr. Meyer serves as the chairman of the board of directors and as chair of the audit committee of INSYS Therapeutics NASDAQ: INSY, a publicly held drug development company focused on pain and oncology. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant. - Steven J. Meyer先生在2009年6月被任命为董事。自2005年Meyer先生担任JVM房地产股份有限公司首席财务官，该公司是以及私人企业，并主要关注于并购、再定位以及为有资质的投资者进行多房产管理。Meyer先生现任职于INSYS疗法公司董事会。INSYS先生任职于Baxter国际股份有限公司的23个年头中，还担任过财务主管、国际业务会计账以及负责全球运营的副总裁。
- Steven J. Meyer was appointed a director by the Board in June 2009. Since 2005 Mr. Meyer has served as the Chief Financial Officer of JVM Realty, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company that provides renal and hospital products. Mr. Meyer served as the Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at Baxter International, Inc. Mr. Meyer serves as the chairman of the board of directors and as chair of the audit committee of INSYS Therapeutics NASDAQ: INSY, a publicly held drug development company focused on pain and oncology. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant.
- Alan Weinstein
-
Alan Weinstein先生在2009年7月被任命为董事会董事。自2000年，Weinstein先生在医院组织和医院运行领域向供应客户提供咨询服务，他同时还同采购组织一起工作。在此之前，Weinstein先生是Premier股份有限公司创始人以及总裁，该公司是向会员医院提供各种分享服务的组织。Weinstein先生在以下公司担任董事，包括血管通路股份有限公司、Precyse公司、缝合快递公司以及开放市场公司，他还任职于弗兰克林大学医药科学院受托人委员会。
Alan Weinstein was appointed a director by the Board in July 2009. Since 2000 Mr. Weinstein has provided consulting services to supplier clients in the areas of hospital organization, hospital operations, and working with GPOs. Mr. Weinstein founded and served as President of Premier, Inc., a national GPO providing services for hospitals nationwide. Mr. Weinstein serves as a director on the board of OpenMarkets, which provides a services and technology platform for efficiently purchasing healthcare equipment, and on the board of trustees of the Rosalind Franklin University of Medicine and Science. Previously, Mr. Weinstein served on the boards of privately held companies in the healthcare industry whose primary customers were hospitals, including: Vascular Pathways, Inc. a medical device company, Precyse (a healthcare services and technology company), SutureExpress (a healthcare services company) and Sterilmed, Inc. (a healthcare services company). - Alan Weinstein先生在2009年7月被任命为董事会董事。自2000年，Weinstein先生在医院组织和医院运行领域向供应客户提供咨询服务，他同时还同采购组织一起工作。在此之前，Weinstein先生是Premier股份有限公司创始人以及总裁，该公司是向会员医院提供各种分享服务的组织。Weinstein先生在以下公司担任董事，包括血管通路股份有限公司、Precyse公司、缝合快递公司以及开放市场公司，他还任职于弗兰克林大学医药科学院受托人委员会。
- Alan Weinstein was appointed a director by the Board in July 2009. Since 2000 Mr. Weinstein has provided consulting services to supplier clients in the areas of hospital organization, hospital operations, and working with GPOs. Mr. Weinstein founded and served as President of Premier, Inc., a national GPO providing services for hospitals nationwide. Mr. Weinstein serves as a director on the board of OpenMarkets, which provides a services and technology platform for efficiently purchasing healthcare equipment, and on the board of trustees of the Rosalind Franklin University of Medicine and Science. Previously, Mr. Weinstein served on the boards of privately held companies in the healthcare industry whose primary customers were hospitals, including: Vascular Pathways, Inc. a medical device company, Precyse (a healthcare services and technology company), SutureExpress (a healthcare services company) and Sterilmed, Inc. (a healthcare services company).
- Kenneth S. Abramowitz
-
Kenneth S. Abramowitz先生在2010年5月被选举为董事会成员。Abramowitz先生是NGN资本公司联合创始人以及常务一般合伙人。他从纽约的Carlyle集团加入我公司，从2001年到2003年，他在该公司担任常务董事，并主要负责美国医疗保健产业市场收购的机会。在此之前，Abramowitz先生在斯坦福C. Bernstein公司大门热门分析师，在该公司他负责药物供应、医院管理以及健康维护组织，他在上述产业任职23年。Abramowitz先生在1972年从哥伦比亚大学获得学士学位，1976年从哈佛大学商学院获得工商管理学硕士学位。Abramowitz先生目前任职于以下公司董事会，包括EKOS公司、OptiScan生物医药公司、Cerapedics股份有限公司、Valtech有氧运动公司以及小骨头创新股份有限公司。他先前在以下公司担任董事，包括选择护理股份有限公司、视线技术有限责任公司、能量医药介入公司以及MedPointe和MedPointe控股公司。
Kenneth S. Abramowitz was elected to the Board in May 2010. Mr. Abramowitz is Managing General Partner of NGN Capital, a venture capital firm that he co-founded in 2003 which focuses on investments in the healthcare and biotechnology sectors. Mr. Abramowitz joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003 and focused on U.S. buyout opportunities in the healthcare industry. Prior to that, Mr. Abramowitz worked as an analyst at Sanford C. Bernstein & Company, where he covered the medical supply, hospital management and health maintenance organization HMO industries for 23 years. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an M.B.A. from Harvard Business School in 1976. Mr. Abramowitz currently sits on the boards of the following privately held companies: OptiScan Biomedical Corporation (a company that develops continuous monitoring systems for use in hospital ICUs), Cerapedics, Inc. (an orthobiologics company), Entera Bio Ltd. (a biotechnology company) and MitralTech Ltd. (a company that develops and manufactures cardiovascular devices for mitral valve replacement). Mr. Abramowitz previously served as a director at EKOS Corp., Small Bone Innovations, Inc., Option Care, Inc., Sightline Technologies Ltd. (acquired by Stryker) and Power Medical Interventions (acquired by Covidien), as well as MedPointe and ConnectiCare Holdings, Inc. - Kenneth S. Abramowitz先生在2010年5月被选举为董事会成员。Abramowitz先生是NGN资本公司联合创始人以及常务一般合伙人。他从纽约的Carlyle集团加入我公司，从2001年到2003年，他在该公司担任常务董事，并主要负责美国医疗保健产业市场收购的机会。在此之前，Abramowitz先生在斯坦福C. Bernstein公司大门热门分析师，在该公司他负责药物供应、医院管理以及健康维护组织，他在上述产业任职23年。Abramowitz先生在1972年从哥伦比亚大学获得学士学位，1976年从哈佛大学商学院获得工商管理学硕士学位。Abramowitz先生目前任职于以下公司董事会，包括EKOS公司、OptiScan生物医药公司、Cerapedics股份有限公司、Valtech有氧运动公司以及小骨头创新股份有限公司。他先前在以下公司担任董事，包括选择护理股份有限公司、视线技术有限责任公司、能量医药介入公司以及MedPointe和MedPointe控股公司。
- Kenneth S. Abramowitz was elected to the Board in May 2010. Mr. Abramowitz is Managing General Partner of NGN Capital, a venture capital firm that he co-founded in 2003 which focuses on investments in the healthcare and biotechnology sectors. Mr. Abramowitz joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003 and focused on U.S. buyout opportunities in the healthcare industry. Prior to that, Mr. Abramowitz worked as an analyst at Sanford C. Bernstein & Company, where he covered the medical supply, hospital management and health maintenance organization HMO industries for 23 years. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an M.B.A. from Harvard Business School in 1976. Mr. Abramowitz currently sits on the boards of the following privately held companies: OptiScan Biomedical Corporation (a company that develops continuous monitoring systems for use in hospital ICUs), Cerapedics, Inc. (an orthobiologics company), Entera Bio Ltd. (a biotechnology company) and MitralTech Ltd. (a company that develops and manufactures cardiovascular devices for mitral valve replacement). Mr. Abramowitz previously served as a director at EKOS Corp., Small Bone Innovations, Inc., Option Care, Inc., Sightline Technologies Ltd. (acquired by Stryker) and Power Medical Interventions (acquired by Covidien), as well as MedPointe and ConnectiCare Holdings, Inc.
- Adrienne L. Graves
-
Adrienne L. Graves， 哲学博士。2005年4月起，她担任董事会成员，2002至2010年，担任Santen Inc.，的总裁和首席执行官，该公司是Santen Pharmaceutical Co., Ltd.的美国子公司。她目前是Santen的战略顾问。1995年，她加入Santen Inc.担任临场事务副总裁，开创了公司在美国的临床发展。 加入Santen Inc.之前，1986年起，她在Alcon Laboratories, Inc., or Alcon担任了9年的高级科学家。1992年，她被任命为Alcon临床科学部门的助理董事，1993年，担任Alcon的国际眼科学董事。她是30多个研究报告的作者，以及多个专业协会的成员，包括视力与眼科学研究协会（Association for Research in Vision and Ophthalmology）、美国眼科学会（American Academy of Ophthalmology）、美国青光眼与女性眼科协会（American Glaucoma Society and Women in Ophthalmology）。她还是美国眼科学基金会学会（American Academy of Ophthalmology Foundation）、全美洲眼科学协会（Pan-American Association of Ophthalmology）、美国白内障和激光手术协会（ American Association for Cataract and Refractive Surgery）、青光眼研究基金会（Glaucoma Research Foundation）和布朗大学医学院公司委员会（Corporation Committee for the Brown University Medical School）的董事会成员。她还是青光眼女性领袖（Ophthalmic Women Leaders）的创始人之一。她在布朗大学（Brown University）以优异成绩获得心理学学士学位，在密西根大学（University of Michigan）获得心理学博士学位，在巴黎大学（University of Paris）完成视觉神经系统科学博士学位。
Adrienne L. Graves, Ph.D. has been a member of TearLab Corporation’s Board since April 2005. From 2002 to 2010 Dr. Graves was President and Chief Executive Officer of Santen Inc. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., beginning in 1986 as a Senior Scientist. Dr. Graves was named Associate Director of Alcon’s Clinical Science Division in 1992 and then Alcon’s Director of International Ophthalmology in 1993. Dr. Graves is the author of over thirty research papers and is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. She also serves on the boards of the American Academy of Ophthalmology Foundation emeritus, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation, and the Corporation Committee for the Brown University Medical School. Dr. Graves also co-founded Ophthalmic Women Leaders. She received her BA in psychology with honors from Brown University, received her Ph.D. in psychobiology from the University of Michigan, and completed a postdoctoral fellowship in visual neuroscience at the University of Paris. - Adrienne L. Graves， 哲学博士。2005年4月起，她担任董事会成员，2002至2010年，担任Santen Inc.，的总裁和首席执行官，该公司是Santen Pharmaceutical Co., Ltd.的美国子公司。她目前是Santen的战略顾问。1995年，她加入Santen Inc.担任临场事务副总裁，开创了公司在美国的临床发展。 加入Santen Inc.之前，1986年起，她在Alcon Laboratories, Inc., or Alcon担任了9年的高级科学家。1992年，她被任命为Alcon临床科学部门的助理董事，1993年，担任Alcon的国际眼科学董事。她是30多个研究报告的作者，以及多个专业协会的成员，包括视力与眼科学研究协会（Association for Research in Vision and Ophthalmology）、美国眼科学会（American Academy of Ophthalmology）、美国青光眼与女性眼科协会（American Glaucoma Society and Women in Ophthalmology）。她还是美国眼科学基金会学会（American Academy of Ophthalmology Foundation）、全美洲眼科学协会（Pan-American Association of Ophthalmology）、美国白内障和激光手术协会（ American Association for Cataract and Refractive Surgery）、青光眼研究基金会（Glaucoma Research Foundation）和布朗大学医学院公司委员会（Corporation Committee for the Brown University Medical School）的董事会成员。她还是青光眼女性领袖（Ophthalmic Women Leaders）的创始人之一。她在布朗大学（Brown University）以优异成绩获得心理学学士学位，在密西根大学（University of Michigan）获得心理学博士学位，在巴黎大学（University of Paris）完成视觉神经系统科学博士学位。
- Adrienne L. Graves, Ph.D. has been a member of TearLab Corporation’s Board since April 2005. From 2002 to 2010 Dr. Graves was President and Chief Executive Officer of Santen Inc. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., beginning in 1986 as a Senior Scientist. Dr. Graves was named Associate Director of Alcon’s Clinical Science Division in 1992 and then Alcon’s Director of International Ophthalmology in 1993. Dr. Graves is the author of over thirty research papers and is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. She also serves on the boards of the American Academy of Ophthalmology Foundation emeritus, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation, and the Corporation Committee for the Brown University Medical School. Dr. Graves also co-founded Ophthalmic Women Leaders. She received her BA in psychology with honors from Brown University, received her Ph.D. in psychobiology from the University of Michigan, and completed a postdoctoral fellowship in visual neuroscience at the University of Paris.
- Brian Tambi
-
Brian Tambi ，自2010年11月以来一直是本董事会的成员。他目前是Akorn股份有限公司的董事会成员。在2007年8月-2010年11月期间，他曾在Insys Pharma任董事。自该公司2006年1月成立以来，他曾在一个目前专注于领先单剂药物和传输系统的开发、生产和营销组合的医药公司- BrianT Laboratories有限责任公司任董事长、总裁兼首席执行官。在1995-2007年1月期间，他曾在Morton Grove Pharmaceuticals股份有限公司担任董事长、总裁兼首席执行官。在加入Morton Grove之前，他曾是一个公开上市的被Teva收购的医药公司- Ivax的董事会成员。他还曾在Fujisawa医药公司的子公司- Fujisawa USA股份有限公司担任首席运营官。他还曾在Lyphomed 股份有限公司和Bristol-Myers Squibb担任数个行政管理职位。他是在Syracuse大学获得他的国际金融和经济工商管理学硕士学位，以及企业财务学士学位。
Brian Tambi has served on our Board since November 2010. From August 2007 until the November 2010 Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006 Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of Antrim Pharma formerly BrianT Laboratories LLC, a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007 Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University. - Brian Tambi ，自2010年11月以来一直是本董事会的成员。他目前是Akorn股份有限公司的董事会成员。在2007年8月-2010年11月期间，他曾在Insys Pharma任董事。自该公司2006年1月成立以来，他曾在一个目前专注于领先单剂药物和传输系统的开发、生产和营销组合的医药公司- BrianT Laboratories有限责任公司任董事长、总裁兼首席执行官。在1995-2007年1月期间，他曾在Morton Grove Pharmaceuticals股份有限公司担任董事长、总裁兼首席执行官。在加入Morton Grove之前，他曾是一个公开上市的被Teva收购的医药公司- Ivax的董事会成员。他还曾在Fujisawa医药公司的子公司- Fujisawa USA股份有限公司担任首席运营官。他还曾在Lyphomed 股份有限公司和Bristol-Myers Squibb担任数个行政管理职位。他是在Syracuse大学获得他的国际金融和经济工商管理学硕士学位，以及企业财务学士学位。
- Brian Tambi has served on our Board since November 2010. From August 2007 until the November 2010 Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006 Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of Antrim Pharma formerly BrianT Laboratories LLC, a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007 Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University.
高管简历
中英对照 | 中文 | 英文- Duane A. Portwood
Duane A. Portwood，加入Akorn之前，他曾在The Home Depot, Inc.任职，自2006年起担任副总裁和企业总监。任职期间，他负责Home Depot所有的会计和金融报告职能部门，以及金融运营和内部控制。加入Home Depot之前，Portwood从1999年到2006年在Wm.Wrigley Jr. Company 担任多个会计和金融领导职位，最近的职位是担任企业总监。Portwood在PricewaterhouseCoopers LLP开始自己的职业生涯，曾在审计和交易支持实践处担任多个职位。Portwood持有 the University of Chicago Booth School of Business荣誉工商管理硕士学位； the University of Montana工商管理理学学士学位。Portwood是一名注册会计师。
Duane A. Portwood joined Akorn from The Home Depot, Inc., where he was their Vice President & Corporate Controller since 2006. In that role, he was responsible for all of Home Depot’s accounting and financial reporting functions, as well as its financial operations and internal controls. Prior to Home Depot, Mr. Portwood served with the Wm. Wrigley Jr. Company from 1999 to 2006 in a number of accounting and finance leadership roles of increasing responsibility, most recently as Corporate Controller. Mr. Portwood began his career with PricewaterhouseCoopers LLP, where he held numerous leadership positions in their audit and transaction support practices. Mr. Portwood holds an M.B.A. with Honors from the University of Chicago Booth School of Business and a B.S. in Business Administration from the University of Montana. Mr. Portwood is a Certified Public Accountant.- Duane A. Portwood，加入Akorn之前，他曾在The Home Depot, Inc.任职，自2006年起担任副总裁和企业总监。任职期间，他负责Home Depot所有的会计和金融报告职能部门，以及金融运营和内部控制。加入Home Depot之前，Portwood从1999年到2006年在Wm.Wrigley Jr. Company 担任多个会计和金融领导职位，最近的职位是担任企业总监。Portwood在PricewaterhouseCoopers LLP开始自己的职业生涯，曾在审计和交易支持实践处担任多个职位。Portwood持有 the University of Chicago Booth School of Business荣誉工商管理硕士学位； the University of Montana工商管理理学学士学位。Portwood是一名注册会计师。
- Duane A. Portwood joined Akorn from The Home Depot, Inc., where he was their Vice President & Corporate Controller since 2006. In that role, he was responsible for all of Home Depot’s accounting and financial reporting functions, as well as its financial operations and internal controls. Prior to Home Depot, Mr. Portwood served with the Wm. Wrigley Jr. Company from 1999 to 2006 in a number of accounting and finance leadership roles of increasing responsibility, most recently as Corporate Controller. Mr. Portwood began his career with PricewaterhouseCoopers LLP, where he held numerous leadership positions in their audit and transaction support practices. Mr. Portwood holds an M.B.A. with Honors from the University of Chicago Booth School of Business and a B.S. in Business Administration from the University of Montana. Mr. Portwood is a Certified Public Accountant.
- Steven Lichter
Steven Lichter，他于2015年早期加入 Akorn，担任执行副总裁，负责制药业务。他离开Abbott Laboratories加入Akorn。他担任Abbott Laboratories的各种领导职位超过32年，最后担任Abbott的瑞士建立制药部门运营公司副总裁。担任该职位是，他负责部门的全球供应链运营，包括积极完成药品制造、采购、制造、工程和商业运作。他获得Northern Illinois University。的工商管理学士学位和硕士学位。
Steven Lichter joined Akorn in early 2015 as Executive Vice President, Pharmaceutical Operations. Mr. Lichter joins Akorn from Abbott Laboratories, where he served in various leadership roles over 32 years, most recently as Corporate Vice President, Operations, for Abbott's Established Pharmaceutical Division in Switzerland. In this role, Mr. Lichter was responsible for the division's global supply chain operations including active and finished drug product manufacturing, procurement, manufacturing, engineering and commercial operations. Mr. Lichter holds a B.S. in Business Management and an M.B.A. from Northern Illinois University.- Steven Lichter，他于2015年早期加入 Akorn，担任执行副总裁，负责制药业务。他离开Abbott Laboratories加入Akorn。他担任Abbott Laboratories的各种领导职位超过32年，最后担任Abbott的瑞士建立制药部门运营公司副总裁。担任该职位是，他负责部门的全球供应链运营，包括积极完成药品制造、采购、制造、工程和商业运作。他获得Northern Illinois University。的工商管理学士学位和硕士学位。
- Steven Lichter joined Akorn in early 2015 as Executive Vice President, Pharmaceutical Operations. Mr. Lichter joins Akorn from Abbott Laboratories, where he served in various leadership roles over 32 years, most recently as Corporate Vice President, Operations, for Abbott's Established Pharmaceutical Division in Switzerland. In this role, Mr. Lichter was responsible for the division's global supply chain operations including active and finished drug product manufacturing, procurement, manufacturing, engineering and commercial operations. Mr. Lichter holds a B.S. in Business Management and an M.B.A. from Northern Illinois University.
- Randall Pollard
Randall Pollard，他于2015年4月离开Novartis Pharmaceuticals加入Akorn。他最后担任Novartis Pharmaceuticals的Novartis的Sandoz分部的核算和报告负责人。在Novartis任职时，他也担任Sandoz部门财务总监。Novartis/Sandoz之前，他担任Wyeth and Mayne Pharma的各种财务领导职位。他的公共会计职业生涯始于任职Arthur Andersen。他是一个注册会计师，并持有Pennsylvania State University的会计学士学位和Fairleigh Dickinson University的工商管理硕士学位。
Randall Pollard joined Akorn in April 2015 as Vice President, Corporate Controller and is currently serving as Senior Vice President, Chief Accounting Officer. Mr. Pollard joined Akorn from Novartis Pharmaceuticals, where he most recently served as the head of accounting and reporting for Novartis’ generic division, Sandoz. During his tenure at Novartis, Mr. Pollard also served as Controller of the Sandoz division. Prior to Novartis/Sandoz, he had served in various financial leadership roles at Wyeth Pharmaceutics and Mayne Pharma. Mr. Pollard began his career in public accounting at Arthur Andersen. Mr. Pollard is a Certified Public Accountant and holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from Fairleigh Dickinson University.- Randall Pollard，他于2015年4月离开Novartis Pharmaceuticals加入Akorn。他最后担任Novartis Pharmaceuticals的Novartis的Sandoz分部的核算和报告负责人。在Novartis任职时，他也担任Sandoz部门财务总监。Novartis/Sandoz之前，他担任Wyeth and Mayne Pharma的各种财务领导职位。他的公共会计职业生涯始于任职Arthur Andersen。他是一个注册会计师，并持有Pennsylvania State University的会计学士学位和Fairleigh Dickinson University的工商管理硕士学位。
- Randall Pollard joined Akorn in April 2015 as Vice President, Corporate Controller and is currently serving as Senior Vice President, Chief Accounting Officer. Mr. Pollard joined Akorn from Novartis Pharmaceuticals, where he most recently served as the head of accounting and reporting for Novartis’ generic division, Sandoz. During his tenure at Novartis, Mr. Pollard also served as Controller of the Sandoz division. Prior to Novartis/Sandoz, he had served in various financial leadership roles at Wyeth Pharmaceutics and Mayne Pharma. Mr. Pollard began his career in public accounting at Arthur Andersen. Mr. Pollard is a Certified Public Accountant and holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from Fairleigh Dickinson University.
- Jonathon Kafer
Jonathon Kafer，他于2015年4月加入Akorn，担任执行副总裁，负责销售和市场营销。他离开Allergan, Inc.加入Akorn。他曾担任 Allergan, Inc.的会计管理副总裁。在Allergan时，他负责Allergan所有专业批发、零售药店、电子解决方案的交易活动，管理Allergan的所有业务单元的市场渠道。Allergan之前，他曾是Teva Pharmaceuticals的卫生系统销售和营销副总裁。他也担任aaiPharma、Xanodyne Pharmaceuticals、HealthNexis和Novartis的各种高级管理职位。他持有The Ohio State University的组织传播学士学位。
Jonathon Kafer joined Akorn in April 2015 as Executive Vice President, Sales and Marketing. Mr. Kafer joins Akorn from Allergan, Inc., where he was previously the Vice President, Account Management. At Allergan, Mr. Kafer was responsible for all trade activity within Allergan's wholesale, retail specialty pharmacy, e-Solutions and managed market channels for all of Allergan's business units. Prior to Allergan, Mr. Kafer was the Vice President of Sales and Marketing for Health Systems at Teva Pharmaceuticals. Mr. Kafer has also served in various senior management roles at aaiPharma, Xanodyne Pharmaceuticals, HealthNexis and Novartis. Mr. Kafer holds a B.A. in Organizational Communications from The Ohio State University.- Jonathon Kafer，他于2015年4月加入Akorn，担任执行副总裁，负责销售和市场营销。他离开Allergan, Inc.加入Akorn。他曾担任 Allergan, Inc.的会计管理副总裁。在Allergan时，他负责Allergan所有专业批发、零售药店、电子解决方案的交易活动，管理Allergan的所有业务单元的市场渠道。Allergan之前，他曾是Teva Pharmaceuticals的卫生系统销售和营销副总裁。他也担任aaiPharma、Xanodyne Pharmaceuticals、HealthNexis和Novartis的各种高级管理职位。他持有The Ohio State University的组织传播学士学位。
- Jonathon Kafer joined Akorn in April 2015 as Executive Vice President, Sales and Marketing. Mr. Kafer joins Akorn from Allergan, Inc., where he was previously the Vice President, Account Management. At Allergan, Mr. Kafer was responsible for all trade activity within Allergan's wholesale, retail specialty pharmacy, e-Solutions and managed market channels for all of Allergan's business units. Prior to Allergan, Mr. Kafer was the Vice President of Sales and Marketing for Health Systems at Teva Pharmaceuticals. Mr. Kafer has also served in various senior management roles at aaiPharma, Xanodyne Pharmaceuticals, HealthNexis and Novartis. Mr. Kafer holds a B.A. in Organizational Communications from The Ohio State University.
- Raj Rai
Raj Rai先生在2009年6月被任命为临时首席执行官，并在2010年5月成为首席执行官。在2009年2月他被任命为董事会特殊委员会策略咨询师，他是在前总裁以及首席执行官卸任后担任此职务的。在加入Akorn之前，Rai先生担任选择护理股份有限公司总裁以及首席执行官，该公司是家庭注射药房和特种药房服务的领先提供商，后来，该公司在2007年8月被Walgreen公司收购。Rai先生先前在SeQual技术股份有限公司担任董事会董事，目前在Aciex疗法公司担任董事会董事。
Raj Rai was appointed Interim Chief Executive Officer in June 2009 and appointed Chief Executive Officer in May 2010. He had been appointed Strategic Consultant to the Special Committee of the Board in February 2009 following the departure of our former President and Chief Executive Officer. Prior to joining Akorn, Mr. Rai was the President and CEO of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. now known as Walgreens Boots Alliance, Inc. in August 2007. Mr. Rai previously served on the board of directors of SeQual Technologies Inc.- Raj Rai先生在2009年6月被任命为临时首席执行官，并在2010年5月成为首席执行官。在2009年2月他被任命为董事会特殊委员会策略咨询师，他是在前总裁以及首席执行官卸任后担任此职务的。在加入Akorn之前，Rai先生担任选择护理股份有限公司总裁以及首席执行官，该公司是家庭注射药房和特种药房服务的领先提供商，后来，该公司在2007年8月被Walgreen公司收购。Rai先生先前在SeQual技术股份有限公司担任董事会董事，目前在Aciex疗法公司担任董事会董事。
- Raj Rai was appointed Interim Chief Executive Officer in June 2009 and appointed Chief Executive Officer in May 2010. He had been appointed Strategic Consultant to the Special Committee of the Board in February 2009 following the departure of our former President and Chief Executive Officer. Prior to joining Akorn, Mr. Rai was the President and CEO of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. now known as Walgreens Boots Alliance, Inc. in August 2007. Mr. Rai previously served on the board of directors of SeQual Technologies Inc.
- Joseph Bonaccorsi
Joseph Bonaccorsi先生与2009年加入Akorn公司并担任高级副总裁、秘书长以及法律总顾问。Bonaccorsi先生从Walgreen公司来到我公司，在该公司担任负责并购的高级副总裁，同时在在Walgreens-选择呵护家庭护理部门担任法律总顾问。在2002年Bonaccorsi先生加入选择护理股份有限公司，并且一直到2007年担任高级副总裁、法律总顾问以及公司合规官。在加入选择护理股份有限公司前，他在伊利诺伊州的芝加哥市从事自己的私人业务。他从西北大学获得硕士学位，从罗耀拉大学法学院芝加哥分校获得法学博士学位。
Joseph Bonaccorsi joined Akorn in 2009 as Senior Vice President, Secretary and General Counsel and was named Executive Vice President, Secretary and General Counsel in 2016. Mr. Bonaccorsi came to Akorn from Walgreen Co., where he served as Senior Vice President Mergers & Acquisition and Counsel for the Walgreens-Option Care Home Care division. Mr. Bonaccorsi joined Option Care, Inc. in 2002 where he served as Senior Vice President, General Counsel, Secretary and Corporate Compliance Officer through 2007. Prior to joining Option Care, Inc., he was in private law practice in Chicago, Illinois. He received his B.S. degree from Northwestern University and his Juris Doctorate from Loyola University School of Law, Chicago.- Joseph Bonaccorsi先生与2009年加入Akorn公司并担任高级副总裁、秘书长以及法律总顾问。Bonaccorsi先生从Walgreen公司来到我公司，在该公司担任负责并购的高级副总裁，同时在在Walgreens-选择呵护家庭护理部门担任法律总顾问。在2002年Bonaccorsi先生加入选择护理股份有限公司，并且一直到2007年担任高级副总裁、法律总顾问以及公司合规官。在加入选择护理股份有限公司前，他在伊利诺伊州的芝加哥市从事自己的私人业务。他从西北大学获得硕士学位，从罗耀拉大学法学院芝加哥分校获得法学博士学位。
- Joseph Bonaccorsi joined Akorn in 2009 as Senior Vice President, Secretary and General Counsel and was named Executive Vice President, Secretary and General Counsel in 2016. Mr. Bonaccorsi came to Akorn from Walgreen Co., where he served as Senior Vice President Mergers & Acquisition and Counsel for the Walgreens-Option Care Home Care division. Mr. Bonaccorsi joined Option Care, Inc. in 2002 where he served as Senior Vice President, General Counsel, Secretary and Corporate Compliance Officer through 2007. Prior to joining Option Care, Inc., he was in private law practice in Chicago, Illinois. He received his B.S. degree from Northwestern University and his Juris Doctorate from Loyola University School of Law, Chicago.
- Bruce Kutinsky
Bruce Kutinsky 博士在2009年晚些时候加入Akorn公司，并担任公司策略部高级副总裁，同时，在2011年5月，在公司被高级视觉研究公司收购后被提名客户健康部总裁。在2012年9月，Kutinsky博士被任命为Akorn公司首席运营官，在加入Akorn公司之前，Kutinsky博士担任Walgreens公司负责策略解决办法的副总裁。在此之前，Kutinsky博士从1997年到2007年在选择呵护公司担任各种职务，且所担任得到最近的一个职务是主管特种药剂的执行副总裁。Kutinsky博士从密歇根大学获得药剂学博士学位。
Bruce Kutinsky joined Akorn in 2010 as Senior Vice President of Corporate Strategy and was named President, Consumer Health Division following the Company's acquisition of Advanced Vision Research, Inc. in May 2011. In September 2012 Dr. Kutinsky was appointed to serve as Akorn's Chief Operating Officer. Before joining Akorn, Dr. Kutinsky was Vice President - Strategic Solutions for Walgreens. Prior to that, Dr. Kutinsky served in various roles at Option Care from 1997 to 2007 the most recent of which was as Executive Vice President, Specialty Pharmacy. Dr. Kutinsky holds a Doctor of Pharmacy degree from the University of Michigan.- Bruce Kutinsky 博士在2009年晚些时候加入Akorn公司，并担任公司策略部高级副总裁，同时，在2011年5月，在公司被高级视觉研究公司收购后被提名客户健康部总裁。在2012年9月，Kutinsky博士被任命为Akorn公司首席运营官，在加入Akorn公司之前，Kutinsky博士担任Walgreens公司负责策略解决办法的副总裁。在此之前，Kutinsky博士从1997年到2007年在选择呵护公司担任各种职务，且所担任得到最近的一个职务是主管特种药剂的执行副总裁。Kutinsky博士从密歇根大学获得药剂学博士学位。
- Bruce Kutinsky joined Akorn in 2010 as Senior Vice President of Corporate Strategy and was named President, Consumer Health Division following the Company's acquisition of Advanced Vision Research, Inc. in May 2011. In September 2012 Dr. Kutinsky was appointed to serve as Akorn's Chief Operating Officer. Before joining Akorn, Dr. Kutinsky was Vice President - Strategic Solutions for Walgreens. Prior to that, Dr. Kutinsky served in various roles at Option Care from 1997 to 2007 the most recent of which was as Executive Vice President, Specialty Pharmacy. Dr. Kutinsky holds a Doctor of Pharmacy degree from the University of Michigan.